Obesity-related colorectal cancer risk differs for men and women

Published in Cancer

Obesity-related colorectal cancer risk differs for men and women
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Obesity is viewed as a likely cause of colorectal cancer (CRC, also known as bowel cancer) [1], but still unclear is whether risk differs for men and women, and exactly how obesity biologically causes CRC. Using a sort of naturally occurring trial called Mendelian randomization [2], which uses genetic information to better understand causality of modifiable factors, we examined whether two different measures of obesity – namely body mass index (BMI) and waist-hip-ratio (WHR) were associated with CRC risk among men and women separately. We also investigated whether circulating metabolites, or small molecules in blood which capture metabolic processes, could explain these relationships [3]. These Mendelian randomization methods, when key assumptions are met, help to minimise issues of confounding and reverse causation which are common pitfalls of observational studies [2].

Obesity is viewed as an important risk factor for cancer by the World Cancer Research Fund (WCRF) https://www.wcrf-uk.org/uk/our-research/research-we-fund

 As part of a collaboration between the International Agency for Research and Cancer (IARC) in France, the Fred Hutchinson Cancer Research Centre in the US, and the University of Bristol in the UK, we acquired summary statistics from three major consortia, including the Genetics of Epidemiology of Colorectal Cancer Consortium (GECCO), together describing the genotypes of over 100,000 individuals from 72 studies to better estimate the role of adiposity in CRC, separately by sex and anatomical sub-site (colon, proximal colon, distal colon and rectum). We used publicly available summary statistics describing the genetics of adiposity (BMI, WHR) and metabolites detected by targeted NMR spectroscopy. These metabolites included detailed lipid traits plus amino acids, fatty acids and inflammatory glycoproteins.

Metabolites detectable in blood using the Nightingale Health NMR panel https://nightingalehealth.com/research/blood-biomarker-analysis

Our results suggest that BMI and WHR associations do not differ substantially by CRC site, but do differ substantially by sex. Higher BMI is more strongly associated with CRC risk in men, whereas higher WHR is more strongly associated with CRC in women. This was surprising as BMI and WHR are highly correlated, and we hypothesise that this could be because women are more likely to store fat peripherally, meaning that WHR is better able to capture the extremes of adiposity in women.

A two-minute primer on Mendelian randomization

We explored potential mechanisms through which adiposity could influence CRC by examining metabolites as intermediate biomarkers. Despite examining over 100 metabolites from multiple biological subclasses, we did not identify any convincing metabolite-CRC associations which could explain the adipose-CRC relationship. Future studies using new and improved methodological techniques and exploring even more detailed metabolites, proteins, hormones, and inflammatory factors as potential mediators are needed to uncover the biological pathways between adiposity and CRC. This should be done among men and women separately given their markedly different risks from obesity. Understanding these pathways is more important than ever because of how common overweight and obesity are, and how difficult they are to reverse.

Read the paper here: https://rdcu.be/cclz2

References

  1. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report. Diet, nutrition, physical activity and colorectal cancer. 2018.
  2. Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003; 32(1): 1–22.
  3. Bull CJ, Bell JA, Murphy N, et al. Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. BMC Med. 2020; 18(1): 396.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Cancer Biology
Life Sciences > Biological Sciences > Cancer Biology
  • BMC Medicine BMC Medicine

    This journal publishes outstanding and influential research in all areas of clinical practice, translational medicine, medical and health advances, public health, global health, policy, and general topics of interest to the biomedical and sociomedical professional communities.

Related Collections

With Collections, you can get published faster and increase your visibility.

Advancing research and management of menopause

BMC Medicine is calling for submissions to our new Collection, Advancing research and management of menopause, focusing on new perspectives and care practices that support individuals during this significant life transition. This Collection seeks to advance the understanding and management of menopause by gathering clinical research on its physiological, psychological, and social dimensions. We welcome submissions that explore topics such as perimenopause, menopausal symptoms, early menopause, and menopausal hormone therapy (MHT) but also innovative interventions that help individuals navigate menopause beyond pharmacological treatment.

The menopause journey, encompassing the climacterium and the natural conclusion of reproductive years, is a pivotal phase in the lifecycle that impacts health and well-being. This Collection aims to consolidate research that addresses the multifaceted aspects of menopause, including its physiological, psychological, and social dimensions, thereby offering a comprehensive view of the experiences faced during this transition.

Advancements in the understanding and management of menopause have opened new avenues for improving health. Research indicates that the heterogeneity of menopause (surgical, spontaneous, induced, early) as well as the heterogeneity of MHT (formulations, duration, age of initiation relative to menopause onset, cyclicity, progestrogen/progestin) can differentially affect outcomes, yet are not as well understood or studied. Studies on menopausal symptoms have enhanced our understanding of their prevalence and impact on daily life. Research on menopausal hormone therapy has evolved, shedding light on its benefits and risks, while growing evidence highlights a number of other effective options for managing common menopausal symptoms. Additionally, the focus on long-term effects of menopause, e.g. osteoporosis and prevention strategies, underscores the necessity for ongoing research and tailored interventions during and after this transition.

Continued exploration in this field promises to yield significant insights, potentially leading to the development of novel therapeutic options, personalized management strategies, and a broader understanding of the heterogeneity of menopause and individuals’ experiences. As research progresses, we may see improved guidelines for addressing early menopause and premature ovarian insufficiency, ultimately empowering individuals to navigate this life stage with confidence and health.

Topics of interest include but are not limited to:

- Management strategies for menopausal symptoms

- MHT: risks and benefits

- Post-menopausal osteoporosis prevention

- Ovarian aging and its implications

- Understanding early menopause and premature ovarian insufficiency

This collection supports and amplifies research related to SDG 3: Good Health & Well-Being and SDG 5: Gender Equality.

Publishing Model: Open Access

Deadline: Jul 17, 2026

Cardiac immunity and inflammation

BMC Medicine invites submissions to a new Collection focused on the interplay between cardiac immunity and inflammation. We welcome original research, translational studies, and comprehensive reviews that elucidate the underlying mechanisms, clinical consequences, and therapeutic opportunities arising from immune-cardiac interactions. By highlighting the importance of this link, we aim to foster collaboration and advance our understanding of how to improve patient outcomes in heart disease.

The intersection of immunity and cardiovascular biology represents a transformative frontier in modern medicine. Recent studies have highlighted the role of immune responses in various heart conditions, including myocarditis, cardiac xenotransplantation, and heart failure. Inflammation is increasingly recognized as a contributing factor to the pathogenesis and residual risk factor of cardiovascular diseases. This Collection aims to explore the mechanisms by which immune responses influence cardiac function, the role of clonal hematopoiesis and heart disease, and the implications of such interactions for cardiac outcomes.

Understanding cardiac immunity and inflammation is crucial for developing more targeted therapies and accurate CVD risk prediction. Past advances provided insights into the inflammatory processes involving cardiovascular conditions, leading to innovative approaches for diagnosis and treatment. For instance, the identification of biomarkers such as C-reactive protein enhances our ability to assess inflammation in patients with cardiovascular disease. Furthermore, the intersection of cardio-oncology has opened new avenues for research into how cancer therapies influence cardiac immune responses, emphasizing the need for a multidisciplinary approach to patient management.

Continued research in this field holds promise for unveiling drug discovery targets and strategies to mitigate inflammation-related cardiac damage. As we deepen our understanding of the immune mechanisms at play, we may see the development of more clinically relevant models of human disease and precision medicine approaches tailored to individual patients. The integration of this knowledge with advancements in technology, such as biomarker discovery and imaging techniques, could revolutionize the way we approach cardiac care.

Topics of interest include (but are not limited to):

  • Role of immunity in cardiovascular biomedicine
  • Systemic and cardiac-specific inflammatory pathways
  • Residual inflammatory risk, e.g. “SMuRF-less but inflamed”
  • Cross-organ communication and immune crosstalk
  • Structural and functional cardiac remodeling driven by inflammation
  • Novel biomarkers and prediction models
  • Clonal hematopoiesis
  • Cardio-oncology & therapy-induced immune modulation
  • The role of immunity in cardiac xenotransplantation including partial heart transplantation
  • Exposome/environmental exposures
  • Epigenetic regulation of cardiac immunity and inflammation
  • Immune memory and trained immunity in cardiovascular contexts
  • Multi-omics integration (epigenomics, transcriptomics, proteomics) in cardiac disease

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.

This Collection supports and amplifies research related to SDG 3 (Good Health and Well Being).

Publishing Model: Open Access

Deadline: Feb 01, 2027